AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Question
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Direct answer
FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN. — bullish pressure on HCM via regulatory milestone achievement and future US commercial royalties.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/catalysts/2026-09-29/astrazeneca-and-hutchmed-submit-us-nda-for-orpathys-plus-tagrisso-in-lung-cancer-c2eafe
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| HCM | ▲Bull | 1–3 months | regulatory milestone achievement and future US commercial royalties | 69 |
| AZN | ▲Bull | 1–3 months | TAGRISSO franchise extension via combination therapy | 62 |
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN. — bullish pressure on HCM via regulatory milestone achievement and future US commercial royalties.
AstraZeneca submitted US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer
- SourceAstraZeneca submitted US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer
- TransmissionFDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.
- SummaryAstraZeneca and HUTCHMED filed a US NDA for the savolitinib plus osimertinib combination. The target indication addresses MET-driven EGFR-mutated non-small cell lung cancer post-progression. Regulatory approval would establish a major commercial therapy option in the second-line NSCLC setting.
- HCMDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- HCM closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- HCM price vs. pre-event level
- HCM volume vs. 20-day average
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN. — bullish pressure on AZN via TAGRISSO franchise extension via combination therapy.
US NDA submission to treat lung cancer patients who progressed on EGFR-TKI therapy
- SourceUS NDA submission to treat lung cancer patients who progressed on EGFR-TKI therapy
- TransmissionFDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.
- SummaryAstraZeneca and HUTCHMED filed a US NDA for the savolitinib plus osimertinib combination. The target indication addresses MET-driven EGFR-mutated non-small cell lung cancer post-progression. Regulatory approval would establish a major commercial therapy option in the second-line NSCLC setting.
- AZNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- AZN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- AZN price vs. pre-event level
- AZN volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| HCM | Bullishagreed | 14.15 2026-09-29 | +3.39% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer · GlobeNewswire Inc. · 2026-09-29
Related catalysts
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.